德琪医药-B（股票代码：06996）近日披露2025年度财务报告，公司迎来重大里程碑——完成首例TCE（T细胞衔接器）项目的对外授权协议。此举不仅验证了其创新药物研发平台的商业价值，更被市场视为企业迈向2026年实现盈利的关键转折点。
年报数据显示，通过战略性对外授权合作，德琪医药成功拓展了国际化商业路径，增强了现金流稳定性。TCE技术平台的成果转化，凸显了公司在肿瘤免疫治疗领域的研发实力与创新潜力。
分析师指出，此次授权合作将加速德琪医药核心管线的商业化进程，为2026年扭亏为盈奠定坚实基础。公司管理层表示，将持续推进多元化的全球合作战略，强化自主研发与对外授权的双轮驱动模式。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.